JP6000122B2 - トリプトリド製品 - Google Patents

トリプトリド製品 Download PDF

Info

Publication number
JP6000122B2
JP6000122B2 JP2012510027A JP2012510027A JP6000122B2 JP 6000122 B2 JP6000122 B2 JP 6000122B2 JP 2012510027 A JP2012510027 A JP 2012510027A JP 2012510027 A JP2012510027 A JP 2012510027A JP 6000122 B2 JP6000122 B2 JP 6000122B2
Authority
JP
Japan
Prior art keywords
cancer
triptolide
compound
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012510027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526148A5 (enExample
JP2012526148A (ja
Inventor
イングリッド グンダ ゲオルグ，
イングリッド グンダ ゲオルグ，
サティシュ プラカシュ パティル，
サティシュ プラカシュ パティル，
アショク ケー． サルジャ，
アショク ケー． サルジャ，
ロイト チュー，
ロイト チュー，
セルウィン エム． ビッカーズ，
セルウィン エム． ビッカーズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of JP2012526148A publication Critical patent/JP2012526148A/ja
Publication of JP2012526148A5 publication Critical patent/JP2012526148A5/ja
Application granted granted Critical
Publication of JP6000122B2 publication Critical patent/JP6000122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2012510027A 2009-05-07 2010-05-07 トリプトリド製品 Active JP6000122B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17624909P 2009-05-07 2009-05-07
US61/176,249 2009-05-07
PCT/US2010/034117 WO2010129918A1 (en) 2009-05-07 2010-05-07 Triptolide prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014137661A Division JP2014185181A (ja) 2009-05-07 2014-07-03 トリプトリド製品

Publications (3)

Publication Number Publication Date
JP2012526148A JP2012526148A (ja) 2012-10-25
JP2012526148A5 JP2012526148A5 (enExample) 2013-06-06
JP6000122B2 true JP6000122B2 (ja) 2016-09-28

Family

ID=42244313

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012510027A Active JP6000122B2 (ja) 2009-05-07 2010-05-07 トリプトリド製品
JP2014137661A Withdrawn JP2014185181A (ja) 2009-05-07 2014-07-03 トリプトリド製品
JP2016002236A Pending JP2016065099A (ja) 2009-05-07 2016-01-08 トリプトリド製品

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014137661A Withdrawn JP2014185181A (ja) 2009-05-07 2014-07-03 トリプトリド製品
JP2016002236A Pending JP2016065099A (ja) 2009-05-07 2016-01-08 トリプトリド製品

Country Status (17)

Country Link
US (1) US8507552B2 (enExample)
EP (1) EP2427467B1 (enExample)
JP (3) JP6000122B2 (enExample)
KR (1) KR101821823B1 (enExample)
CN (1) CN102596977B (enExample)
AU (1) AU2010245669B2 (enExample)
BR (1) BRPI1014802B8 (enExample)
CA (2) CA2760953C (enExample)
DK (1) DK2427467T3 (enExample)
EA (1) EA021135B1 (enExample)
ES (1) ES2552163T3 (enExample)
MX (1) MX2011011776A (enExample)
MY (1) MY160392A (enExample)
PL (1) PL2427467T3 (enExample)
PT (1) PT2427467E (enExample)
SG (1) SG175885A1 (enExample)
WO (1) WO2010129918A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
DK3510860T3 (da) 2012-08-23 2021-10-18 Senestech Inc Nedsættelse af pattedyrs reproduktive kapacitet
WO2014047783A1 (zh) * 2012-09-25 2014-04-03 鼎泓国际投资（香港）有限公司 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用
WO2014167581A2 (en) * 2013-04-01 2014-10-16 Laurus Labs Private Limited An improved process for the preparation of triptolide prodrugs
JP6931228B2 (ja) * 2015-09-11 2021-09-01 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体と他の抗癌剤とを組み合わせた癌治療用組成物
CN109942665B (zh) * 2018-04-02 2021-04-06 欣凯医药化工中间体（上海）有限公司 雷公藤内酯醇衍生物及其制备方法和应用
CN110551171B (zh) * 2018-05-31 2021-07-27 欣凯医药化工中间体（上海）有限公司 一种雷公藤内酯醇衍生物的制备方法
CN113056474A (zh) * 2018-09-13 2021-06-29 米尼阿姆里塔治疗学有限责任公司 用于治疗纤维化、nash和nafld的方法中的雷公藤内酯及其前药
WO2021221179A1 (ja) * 2020-04-28 2021-11-04 国立大学法人高知大学 ヒト膵癌オルガノイドを用いたマウスモデルの樹立
US20230303618A1 (en) 2020-08-21 2023-09-28 Reyoung Corporation Triptolide conjugates and uses thereof
CN115227829B (zh) * 2022-02-22 2023-10-13 成都中医药大学 酸敏感性适配体雷公藤甲素偶联物及应用
KR102821060B1 (ko) 2023-03-09 2025-06-16 미네암리타 테라퓨틱스, 엘엘씨 위암의 치료를 위한 약물 조합
KR20250154513A (ko) 2023-03-09 2025-10-28 미네암리타 테라퓨틱스, 엘엘씨 췌장암 치료용 약물 조합
WO2024187139A1 (en) 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of gastric cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5759550A (en) 1993-05-06 1998-06-02 Pharmagenesis, Inc. Method for suppressing xenograft rejection
US5609991A (en) 1995-02-10 1997-03-11 Morton International, Inc. Photoimageable composition having improved alkaline process resistance and tack-free surface for contact imaging
US5663335A (en) 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US5962516A (en) 1997-02-28 1999-10-05 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6548537B1 (en) 1998-09-02 2003-04-15 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
DE69909633T2 (de) * 1998-09-02 2004-05-13 Pharmagenesis, Inc., Palo Alto Gut wasserlösliche triptolid-prodrugs
AU3365800A (en) 1999-02-16 2000-09-04 Board Of Trustees Of The Leland Stanford Junior University Combined therapy of diterpenoid triepoxides and trail for synergistic killing oftumor cells
AU5368699A (en) 1999-04-16 2000-11-02 Chengdu Diao Pharmaceutical Group Company Limited Derivatives of triptolide, and preparation and uses thereof
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6620843B2 (en) * 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
US6569893B2 (en) * 2001-03-15 2003-05-27 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents
UA77033C2 (uk) * 2001-12-21 2006-10-16 Mgi Gp Inc Спосіб отримання водорозчинних фосфонооксиметильних похідних спирту та фенолу
US7847109B2 (en) 2002-05-31 2010-12-07 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
CN100398544C (zh) * 2002-09-18 2008-07-02 成都达远药物有限公司 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用
AU2003297211A1 (en) 2002-12-17 2004-07-22 Pharmagenesis, Inc. Triptolide derivatives as immunomodulator and anticancer agents
CN1223595C (zh) 2002-12-27 2005-10-19 中国科学院上海药物研究所 雷公藤内酯醇衍生物及其应用
US6943259B2 (en) 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
WO2005020887A2 (en) 2003-06-27 2005-03-10 Pharmagenesis, Inc. Method for treatment of severe acute respiratory syndrome
US7820834B2 (en) 2003-12-24 2010-10-26 Pharmagenesis, Inc. Triptolide 5,6-derivatives as immunomodulators and anticancer agents
JP5252765B2 (ja) 2003-12-26 2013-07-31 学校法人東京薬科大学 皮脂産生抑制剤及び皮脂腺発達抑制剤、並びに、皮膚外用剤
ATE554758T1 (de) 2004-03-02 2012-05-15 Pharmagenesis Inc Triptolid-lacton-ring-derivate als immunmodulatoren und mittel gegen krebs
US20070244080A1 (en) 2004-06-25 2007-10-18 Pharmagenesis, Inc. Method for Treatment of Inflammatory Disorders Using Triptolide Compounds
WO2007025031A2 (en) * 2005-08-24 2007-03-01 Cephalon, Inc. Prodrugs of indanone and tetralone compounds
CN101049300A (zh) 2006-04-04 2007-10-10 中国科学院上海药物研究所 包含雷公藤内酯醇衍生物的药物组合物、其剂型和应用
CA2658793A1 (en) * 2006-07-25 2008-02-07 Daniel Dumas Quinoline derivatives
EP2133355A4 (en) * 2007-03-06 2011-12-28 Eisai R&D Man Co Ltd COMPOSITION WITH A CHLOROMETHYPHOSPHATE DERIVATIVE WITH INCREASED STABILITY AND METHOD FOR THE PRODUCTION THEREOF
FI20070574A0 (fi) * 2007-07-30 2007-07-30 Kuopion Yliopisto Vesiliukoinen propofolin etylideenifosfaatti-aihiolääke
WO2009023201A1 (en) 2007-08-16 2009-02-19 Myelorx Llc Rigid derivatives of triptolide as anticancer, immune suppressant, anti-fibrosis, and cns protectant agents

Also Published As

Publication number Publication date
CA2760953C (en) 2017-05-30
EP2427467A1 (en) 2012-03-14
EP2427467B1 (en) 2015-08-05
PL2427467T3 (pl) 2016-04-29
EA201190293A1 (ru) 2012-11-30
CA2760953A1 (en) 2010-11-11
MY160392A (en) 2017-03-15
WO2010129918A1 (en) 2010-11-11
ES2552163T3 (es) 2015-11-26
WO2010129918A8 (en) 2011-01-20
JP2014185181A (ja) 2014-10-02
AU2010245669A1 (en) 2011-12-01
KR20120015339A (ko) 2012-02-21
JP2016065099A (ja) 2016-04-28
US8507552B2 (en) 2013-08-13
MX2011011776A (es) 2012-08-03
BRPI1014802B1 (pt) 2020-09-24
AU2010245669B2 (en) 2015-11-26
KR101821823B1 (ko) 2018-01-24
CN102596977A (zh) 2012-07-18
HK1168107A1 (en) 2012-12-21
DK2427467T3 (en) 2015-11-09
CA2964631A1 (en) 2010-11-11
CN102596977B (zh) 2016-06-29
SG175885A1 (en) 2011-12-29
JP2012526148A (ja) 2012-10-25
BRPI1014802B8 (pt) 2021-05-25
PT2427467E (pt) 2015-11-19
BRPI1014802A2 (pt) 2016-04-05
US20120238529A1 (en) 2012-09-20
EA021135B1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
JP6000122B2 (ja) トリプトリド製品
US10183033B2 (en) Triptolide prodrugs
JP5707131B2 (ja) 抗炎症性化合物とその用途
JP7688098B2 (ja) オキサチアジン様化合物を作製する方法
CA2885740A1 (en) Compounds and compositions for use in the prevention and treatment of inflammation-related disorders, pain and fever, skin disorders, cancer and precancerous conditions thereof
CN107021961B (zh) 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
CN104860932B (zh) 一种吡唑啉酮类化合物及其应用
KR101629077B1 (ko) 편평세포 암종 및 간암에 대한 억제제인 스틸베노이드 화합물 및 그의 용도
HK1168107B (en) Triptolide prodrugs
WO2011147254A1 (zh) 苯丁酰基姜黄素衍生物及其在制备抗肿瘤药物中的应用
CN102649750B (zh) 姜黄素水杨酰单酯及其合成方法以及其在抗肿瘤、抗炎方面的应用
TW201513849A (zh) 藉由合成之帕那司托（ｐａｎａｘｙｔｒｉｏｌ）類似物之毒性下降
CN105326819B (zh) Guttiferone K的医药用途
HK1147912B (en) Anti-inflammatory compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140403

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150417

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150424

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160830

R150 Certificate of patent or registration of utility model

Ref document number: 6000122

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250